Simulations Plus, Inc. $SLP Shares Acquired by Royce & Associates LP

Royce & Associates LP lifted its position in Simulations Plus, Inc. (NASDAQ:SLP) by 31.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 348,758 shares of the technology company’s stock after purchasing an additional 83,758 shares during the quarter. Royce & Associates LP owned about 1.73% of Simulations Plus worth $5,256,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Simulations Plus in the second quarter valued at $25,000. CWM LLC boosted its position in Simulations Plus by 3,729.1% during the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock worth $32,000 after purchasing an additional 2,051 shares in the last quarter. Farther Finance Advisors LLC acquired a new stake in Simulations Plus in the third quarter valued at approximately $40,000. AlphaQuest LLC acquired a new stake in Simulations Plus in the 2nd quarter valued at $69,000. Finally, US Bancorp DE increased its holdings in Simulations Plus by 32.5% in the 3rd quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock worth $93,000 after acquiring an additional 1,513 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Trading Up 4.1%

Shares of SLP stock opened at $12.35 on Thursday. Simulations Plus, Inc. has a twelve month low of $11.16 and a twelve month high of $36.45. The company’s 50-day moving average price is $16.32 and its 200-day moving average price is $16.42. The stock has a market cap of $248.85 million, a price-to-earnings ratio of -3.86 and a beta of 1.17.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The firm had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same period last year, the firm earned $0.17 earnings per share. As a group, equities research analysts predict that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on SLP. BTIG Research downgraded shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. TD Cowen reissued a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Finally, Zacks Research lowered Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Three investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.00.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.